Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2026

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )
1 Jun 2026

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Dr Luke Joseph Peppone - University of Rochester Medical Center, Rochester, USA
Bupropion shows benefit for cancer-related fatigue in cancer survivors ( Dr Luke Joseph Peppone - University of Rochester Medical Center, Rochester, USA )
1 Jun 2026

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada
Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer ( Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada )
1 Jun 2026

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )
1 Jun 2026

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger
ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )
1 Jun 2026

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

Dr Barbara Burtness - Yale Cancer Center, New Haven, USA
Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo ( Dr Barbara Burtness -  Yale Cancer Center, New Haven, USA )
1 Jun 2026

GLP-1 therapy associated with reduced breast cancer risk

Dr Elizabeth McDonald - University of Pennsylvania, Philadelphia, USA
GLP-1 therapy associated with reduced breast cancer risk ( Dr Elizabeth McDonald - University of Pennsylvania, Philadelphia, USA )
1 Jun 2026

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Dr Robert Stein - University College London, London, UK
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )
1 Jun 2026

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA
Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )
1 Jun 2026

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

Dr Peter Sasieni - Queen Mary University of London, London, UK
MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV ( Dr Peter Sasieni - Queen Mary University of London, London, UK )
1 Jun 2026

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )
1 Jun 2026